UAE approves use of new drug to treat vitiligo
The UAE has approved the use of a new drug to treat vitiligo. The drug, called Rinvok, is designed for the treatment of non-segmental vitiligo, for those aged over 12. The Emirates Drug Authority announced on Monday that the UAE was the first country in the world to adopt the drug. Vitiligo is a condition which causes loss of skin colour in patches. It causes the loss of pigment cells, often…
The United Arab Emirates has authorized the use of a novel medication, Rinvok, for treating vitiligo. This drug is specifically formulated for non-segmental vitiligo and is intended for individuals over the age of 12. The Emirates Drug Authority announced on Monday that the UAE was the first nation globally to accept Rinvok. Vitiligo is a skin disorder that results in patchy loss of pigmentation, caused by the disappearance of pigment cells.
This condition affects between 0.5 and 1 percent of the global population and currently has no known cure. The Emirates Drug Authority stated that the UAE's adoption of Rinvok's expanded use signifies the country's advanced standing in embracing cutting-edge pharmaceutical advancements and expediting their accessibility. This approval occurs within a sophisticated regulatory framework that responds to international scientific progressions, thereby contributing to the pharmaceutical sector's growth and enhancing treatment results for patients.
Written by urgent.news from The National Business's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- UAE approves use of new drug to treat vitiligo thenationalnews.com
